Staying on 2.5mg Mounjaro: can it actually produce weight loss?

The misconception: 2.5mg is just a placeholder with no real effect

The most common assumption people bring to this question is that nothing useful happens at 2.5mg, that it is essentially a dummy stage before the medicine "switches on". That is not accurate. Tirzepatide activates both the GIP and GLP-1 receptors from the very first dose. Appetite signals reduce, gastric emptying slows, and early satiety often sets in within the first week or two. Some patients notice they are eating noticeably less before they have even completed their first pen.

So weight loss at 2.5mg is genuinely possible, and our guide on losing weight at 2.5mg Mounjaro goes into detail on what that can realistically look like in practice. The reason it is framed as a starter dose is not because it does nothing, but because clinical trials found that people who moved through a titration schedule reached much larger average losses. The SURMOUNT-1 trial in the New England Journal of Medicine showed average body-weight reductions of around 20–21% over 72 weeks at 15mg, figures achieved by moving progressively through the dose schedule, not by staying at the lowest rung.

In short: 2.5mg can move the needle, but it is unlikely to move it as far as higher doses for most people. That distinction matters if you are weighing up whether to hold your dose or push on. There is more on how the 5mg dose compares in practice on our 5mg weight-loss guide.

When staying at 2.5mg might be clinically appropriate

There are real situations where a prescriber might advise staying at 2.5mg beyond the standard four weeks. Side effects are the most common reason. GI symptoms (nausea, loose stools, indigestion) tend to be most pronounced at the start of treatment or after a dose increase. If those symptoms are still unsettled after four weeks, moving up may not be the right call yet. A brief hold at 2.5mg gives the body more time to adjust before adding any extra demand.

Other clinical factors can also be relevant. Certain medicines interact with tirzepatide's effect on gastric emptying, and your prescriber may want to monitor how things settle before titrating. People managing multiple health conditions sometimes need a slower schedule. None of this means 2.5mg becomes the permanent destination, it means the path to an effective maintenance dose is individual, not just a calendar.

If you are finding early side effects significant, the Mounjaro overview covers what to expect during the first few weeks and what typically settles on its own. Worth reading before you decide anything. If you are specifically wondering whether staying at 2.5mg is the right call for your situation, our guide on holding the dose for weight loss goes deeper on the clinical reasoning.

What the evidence actually shows about low-dose weight loss

SURMOUNT-1 did not include a 2.5mg maintenance arm, which means there is no head-to-head data comparing "staying at 2.5mg" against higher doses in a controlled setting. What the trial does show is a clear dose-response pattern: greater average losses at 10mg and 15mg than at lower doses, across thousands of participants. NICE's appraisal of tirzepatide (TA1026) drew on this data when recommending a titrated-dose approach as part of its criteria.

That dose-response relationship is why the licensed schedule is designed the way it is. The 2.5mg starting dose was chosen to minimise early side effects; the escalation steps are designed to get patients to a dose where the clinical benefit is most reliably seen. Some people reach that point at 5mg or 7.5mg. Others go further. The prescriber's job is to work out where that is for you, not to chase the highest dose for its own sake, but to find the level that delivers meaningful weight reduction without creating side effects that make treatment unsustainable.

People who are not seeing movement on a higher dose often have different questions, our page on not losing weight on 7.5mg addresses that scenario directly, which is a very different clinical picture from wondering about 2.5mg.

How to have this conversation with your prescriber

If you are currently on 2.5mg and questioning what to do next, that conversation belongs with the prescriber who reviews your treatment. The right question is not "should I stay or go up" in the abstract, it is: what is the clinical rationale for my current dose, what results would prompt a change, and what should I be monitoring in the meantime.

At nume, every repeat order goes through a fresh clinical review before it is approved. A named prescriber reads your check-in, considers your progress and any side effects, and makes the dose decision accordingly. There is no automated tick-box. When your pen arrives via DPD in plain packaging you can track it to your door, you know a real clinical decision preceded it.

If you want a clearer picture of how Mounjaro doses work across the whole schedule, our 5mg Mounjaro page explains what most people experience once they step up. And if you are weighing up whether to start treatment at all, the free consultation is the most direct way to get a prescriber's view on your specific situation, no obligation, reviewed the same day.